Practical implementation of automated closed-loop insulin delivery: A French position statement

Area of Science:

• Endocrinology
• Diabetes Technology
• Medical Device Regulation

Background:

• Automated closed-loop (CL) insulin therapy represents a significant advancement in type 1 diabetes management.
• Improving access and adherence to CL therapy requires clear guidelines for patients and healthcare professionals.
• The French Diabetes Society (SFD) convened an expert working group to establish a practical consensus.

Purpose of the Study:

• To define the indications for automated closed-loop insulin therapy.
• To propose specifications for expert care centers initiating CL therapy.
• To emphasize the importance of patient and healthcare professional training and long-term follow-up.

Main Methods:

• Development of a national consensus statement by a French Working Group of experts.
• Discussion and agreement on practical aspects of CL therapy implementation.
• Inclusion of safety, regulatory, ethical, and practical considerations.

Main Results:

• Defined indications for CL therapy, stressing the need for clear treatment expectations.
• Proposed specifications for expert care centers responsible for initiating CL therapy.
• Highlighted the critical role of high-quality training for patients and HCPs.

Conclusions:

• Automated closed-loop insulin therapy is poised to enhance care for individuals with type 1 diabetes.
• This consensus statement provides a framework for integrating CL devices into standard clinical practice.
• Emphasis on defined expectations, specialized care, comprehensive training, and psychosocial factors is crucial for successful adoption.